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Abstract Alzheimer’s disease (AD) is a severe
neurodegenerative disorder characterized mainly by
accumulation of amyloid-b plaques and neurofibril-
lary tangles, synaptic and neuronal loss. Blood
platelets contain the neurotransmitter serotonin and
amyloid-precursor protein (APP), and may thus be
useful as a peripheral biomarker for AD. The aim of
the present study was to functionally characterize
platelets by FACS, to examine alterations in APP
expression and secretion, and to measure serotonin
levels in hypercholesterolemia mice with AD-like
pathology and in two AD mouse models, the triple
transgenic AD model (3xTg) and the APP overex-
pressing AD model with the Swedish–Dutch–Iowa
mutations (APP_SweDI). These data are supplement-
ed with epidermal growth factor (EGF) levels and
compared with changes observed in platelets of
patients with AD. We observed decreased platelet
APP isoforms in 3xTg mice and patients with AD
when analysed by means of Western blot. In patients, a
significant increase of APP levels was observed when
assessed by ELISA. Secreted APPb proved to be
altered amongst all three animal models of AD at
different time points and in human patients with AD.
Serotonin levels were only reduced in 7 and 14 month
old 3xTg mice. Moreover, we found significantly
lower EGF levels in human AD patients and could
thereby reproduce previous findings. Taken together,
our data confirm that platelets are dysfunctional in
AD, however, results from AD animal models do not
coincide in all aspects, and markedly differ when
compared to AD patients. We support previous data
that APP, as well as EGF, could become putative
biomarkers for diagnosing AD in human platelets.
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Introduction
Alzheimer’s disease (AD) is a progressive neurode-
generative disease that gradually leads to severe
cognitive deterioration and premature death. The main
neuropathological hallmarks of AD concurrently
include accumulation of amyloid-b (Ab) plaques,
neurofibrillary tangles (NFT), inflammation and glial
responses, synaptic and neuronal loss and vascular
alterations. In addition, reduced acetylcholine con-
centrations as well as a severe decrease of monoamine
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transmitters serotonin, dopamine and norepinephrine
are observed in patients with AD (Trillo et al. 2013).
AD is classified into clinically indistinguishable
early-onset familiar AD (EOAD) and late-onset spo-
radic AD (LOAD). While EOAD accounts for
approximately 1–5 % of all cases and is associated
with autosomal dominantly inherited mutations with a
high penetrance, LOAD accounts for[95 % of all AD
cases and turned out to be a complex heterogeneous
disease. Effectively, the diagnosis of possible or
probable AD requires according to the current Na-
tional Institute of Neurological and Communicative
Disorders and Stroke and the AD and Related
Disorders Association (NINCDS–ADRDA) criteria
both the presence of cognitive impairment established
by clinical and neuropsychological examination and
the absence of other diseases capable of producing a
dementia syndrome, while definite AD diagnosis still
requires post-mortem evaluation of plaques and NFTs
in brain tissue (McKhann et al. 1984; Dubois et al.
2007). Thus, the diagnosis of AD within the clinical
routine is based on a time consuming combination of
psychological testing, imaging and the analysis of
three well-established biomarkers (amyloid-b42
(Ab42), total tau and phospho-tau-181) in cere-
brospinal fluid (CSF) (Blennow 2005; Blennow et al.
2010; Zetterberg et al. 2010; Tapiola et al. 2009;
Dubois et al. 2007). The increasing rate of AD cases
not only stresses the establishment of efficient
therapeutic intervention, but also the identification of
economic and reliable biomarkers in blood, urine, or
saliva since CSF collection is an invasive procedure
and an expensive analysis (Humpel 2011). We and
others extensively searched for biomarkers in plasma/
serum (Blennow et al. 2010; Ray et al. 2007; Song
et al. 2009; Hu et al. 2012; Chiu et al. 2013), peripheral
blood mononuclear cells (Hu et al. 2014; Kassner et al.
2008), monocytes (Hochstrasser et al. 2012a; Naert
and Rivest 2013; Shad et al. 2013; Bradshaw et al.
2013) or platelets (Adolfsson et al. 1980; Di Luca et al.
1996; Borroni et al. 2010; Casoli et al. 2010;
Marksteiner and Humpel 2013).
Platelets can be considered a valid peripheral model
to study metabolic mechanisms related to AD: these
anuclear blood cells share several biochemical and
homeostatic functions with neural cells such as
accumulation and release of neurotransmitters like
serotonin, glutamate and dopamine, and expression of
membrane-bound components as receptors and
enzymes (El Haouari and Rosado 2009). Also, human
platelets are known to be the most important source for
more than 90 % of the circulating APP (Li et al. 1994;
Padovani et al. 2001) and store Ab (especially Ab40) in
their granules, which is released upon stimulation by
physiological agonists like thrombin, collagen or
calcium ionophores (Li et al. 1999; Bush et al. 1990;
Kokjohn et al. 2011; Skovronsky et al. 2001).
Recently, also tau protein, the major component of
NFTs seen in AD, has been identified in platelet
proteome (Neumann et al. 2011). Moreover, platelets
are known to play an important role in a variety of
cardiovascular, psychosomatic, psychiatric and neu-
rodegenerative diseases. On these grounds, platelets
have been a promising target within the search for
peripheral biomarkers in AD.
Up to now, several studies have reported significant-
ly lower platelet APP ratio (i.e. the ratio between the
upper 130 kDa and the lower 106–110 kDa isoforms)
in AD patients correlating positively with cognitive
decline (Di Luca et al. 1996, 1998; Borroni et al. 2004;
Tang et al. 2006; Zainaghi et al. 2012). Discrepant
results regarding platelet serotonin concentration,
processing and uptake have been published: increased
and decreased, as well as unchanged serotonin
metabolism were reported, precluding a final eval-
uation on platelet serotonin status in AD (Tukiainen
et al. 1981; Andersson et al. 1991; Proksˇelj et al. 2014;
Mimica et al. 2008; Muck-Seler et al. 2009; Kumar
et al. 1995; Koren et al. 1993; Arora et al. 1991).
Decreased platelets EGF, as well as increased sAPPb
levels in patients with AD and MCI were previously
reported by our group (Hochstrasser et al. 2012b;
Marksteiner and Humpel 2013). Other platelet com-
ponents such as activation, membrane fluidity or
enzymatic activity have been investigated in patients
with AD, inconsistent results have, however, to date
impeded the establishment of a valid platelet-derived
biomarker.
Mutant mouse models exhibiting traits such as
plaque and tangle pathology, vascular aberrations and
cognitive decline similar to those seen in AD have
been widely used in AD research. However, transgenic
AD mouse models represent more a familiar form of
AD and reflect only partly the entire AD pathology.
The APP_SweDI mouse model, harbouring the
Swedish K670N/M671L and vasculotropic Dutch/
Iowa E693Q/D694N mutations, is a well-established
model showing severe Ab plaque-like depositions
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starting at 6 months of age, cognitive decline and
vascular pathology including cerebral amyloid an-
giopathy (CAA) but no tau pathology (Davis et al.
2004). The triple-transgenic model (3xTg) however,
develops a neuropathological phenotype including
besides synaptic dysfunction both Ab plaques and
tangle pathology at late stage (Oddo et al. 2003).
Along with genetic interventions, weak traits of
sporadic AD and visible cognitive decline are seen
in different animals and AD mouse models with
hypercholesterolemia (Sparks et al. 1994; Ullrich et al.
2010). While cholesterol diet triggers in wildtype
control mice a weak decline in cognition most
pronounced at 7 months, it elicits only very weak
AD-like pathology (Hohsfield et al. 2014). Thus, the
three mouse models may partly reflect AD pathology
and are a useful tool to study AD-related processes.
While recently platelet activation and thrombus for-
mation in APP23 mice was investigated (Jarre et al.
2014), to the best of our knowledge platelet APP,
sAPPb and serotonin have not been studied in
hypercholesterolemia and the two AD (APP_SweDI
and 3xTg) mouse models.
The aim of the present study is to extensively
characterize AD-related alterations of platelet APP
processing and secretion of sAPPb, and to measure
serotonin levels in three different mouse models: the
hypercholesterolemia mouse model, the triple trans-
genic model displaying Ab plaques and tau pathology
at late stage, and the APP_SweDI mouse model
showing Ab plaques at an early stage, but no tau
pathology. These data will be supplemented and




Wildtype (WT, 129/C57BL6 or C57BL/6N), triple-
transgenic AD (3xTg-AD, B6; 129-Psen1tm1Mpm-
Tg(APPSwe, tauB301L)1Lfa/J) and transgenic
APP_SweDI (Tg-SweDI; expressing amyloid precursor
protein (APP) harboring the Swedish K670N/M671L,
Dutch E693Q, and Iowa D694N mutations; C57BL/6-
Tg(Thy1-APPSwDutIowa) BWevn/Mmjax) mice were
purchased from The Jackson Laboratory and housed at
the Medical University of Innsbruck animal facility
providing open access to food and water under 12/12 h
light–dark cycles. All animals were genotyped accord-
ing to standardized methods. At 2 months of age,
wildtype mice began to receive either a normal diet or a
well-established 5 % cholesterol diet as described by us
in detail (Ullrich et al. 2010; Hohsfield et al. 2014). The
cholesterol containing nutrition was composed of:
450 g/kg cornstarch, 140 g/kg casein, 155 g/kg mal-
todextrin, 100 g/kg sucrose, 40 g/kg soybean oil,
50 g/kg fiber, 35 g/kg mineral mix, 1.8 g/kg L-cystine,
1.4 g/kg choline chloride, 0.0008 g/kg butylhy-
droxytoluol, 10 g/kg vitamin mix (without folic acid),
1 g/kg chocolate aroma, 0.002 g/kg folic acid and
50 g/kg cholesterol for animals on the cholesterol diet
(ssniff special diet, Soest, Germany). All animal
experiments were approved by the Austrian Ministry
of Science and Research (BMWF-66.011/0044-II/3b/
2011 and BMWF-66.011/0059-II/3b/2011) and con-
formed to the Austrian guidelines on animal welfare and
experimentation. All possible steps were taken to
reduce suffering and the number of animals used during
the experiment.
Patients
Cognitively healthy subjects and patients suffering
from AD were recruited at the Landeskrankenhaus
Hall/Tirol, Austria. Thirty healthy persons (10 men
and 20 women, aged 77 ± 1 years) and 43 patients
with AD (18 men and 25 women, aged 80 ± 1 years)
were included in this study. Both groups were assessed
by the same diagnostic procedure. Diagnosis of AD
was established by a structured routine process
including clinical assessment, extensive neuropsycho-
logical tests (including mini-mental state examination,
MMSE) and neuroimaging (magnetic resonance imag-
ing, MRI) to exclude other brain pathologies. Probable
AD was diagnosed according to the current NINCDS–
ARDRA criteria and confirmed for all participating
patients. A general blood examination was part of the
routine diagnostic procedure. Exclusion criteria for
healthy subjects, MCI and AD patients included (1)
another primary neurological or mental disorder, (2)
any kind of metabolic decompensation or any sign of
peripheral inflammation (e.g. rheumatic disease), (3)
long-term alcohol or drug abuse, (4) or any current,
clinically significant cardiovascular disease. The study
was approved by the ethics committee of Medical
University of Innsbruck. All subjects and/or their
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caregivers enrolled in the study gave their informed
consent.
Isolation of mouse platelets and processing
Mouse platelets were isolated as reported previously
(Marksteiner and Humpel 2013). Briefly, mice were
anaesthetized by an intraperitoneal injection of sodi-
um thiopental (12.5 mg/ml, 1 ml; Sandoz, Kundl,
Austria). Blood drawn directly from the heart was
immediately collected in ethylenediaminetetraacetate
(EDTA) tubes (S-monovettes, Sarstedt, Germany),
gently mixed and instantly centrifuged at 1009g for
10 min in order to part platelet rich plasma (PRP). PRP
(upper phase) was collected and prostaglandine 2
(PGI2, 500 nM, Sigma, Vienna, Austria) added
according to the obtained quantity of PRP (19 ll/ml)
to avoid platelet activation during processing. Next,
PRP was partitioned into two portions and then
centrifuged at 4009g for 10 min to isolate platelets.
An aliquot was dissolved in Tyrode buffer (136 mM
NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.42 mM
NaH2PO4, 1 mM MgSo4, 5 mM glucose, pH 6.5)
and immediately analysed (6 ll) by FACS. The rest
was dissolved in 100 ll 1 9 secretase buffer (20 mM
sodium acetate, 0.2 % Triton, pH 4.5), sonicated with
a Branson sonifier (10 strokes each 10 s on ice), then
centrifuged at 16,0009g for 10 min and the super-
natant was collected, total protein was measured using
the Bradford protein assay and the rest was frozen at
-80 C until use.
Isolation of human platelets and processing
Human platelets were isolated as previously described
(Marksteiner and Humpel 2013). In short, 10 ml blood
was collected in EDTA tubes during normal clinical
routine, centrifuged at 2509g for 10 min at RT to
collect platelet-rich plasma (PRP). PRP was centrifuged
for 10 min at RT (23009g) and the pellet was dissolved
in 1 ml Tyrode’s buffer and PGI2 was added in order to
inhibit platelet activation. Next, the dissolved pellet was
partitioned into three portions with each 330 ll and then
centrifuged at 23009g for 10 min.
Sample A-human
The pellet was resuspended in 150 ll secretase buffer
(20 mM sodiumacetate, 0.2 % Triton, pH 4.5),
sonicated with a Branson sonifier (10 strokes each
10 s on ice), then centrifuged at 14,0009g for 10 min
and total protein determined by Bradford assay. The
rest was frozen at -80 C until use.
Sample B-human
The pellet was resuspended in 100 ll phosphate
buffered saline (PBS) with a protease inhibitor cock-
tail (Sigma), sonicated with a Branson sonifier (10
strokes each 10 s on ice, 125 W/cm2, 140 lm ampli-
tude, 100 %), and centrifuged at 14,0009g for 10 min.
The supernatant was collected, again the total protein
determined and frozen at -80 C.
Sample C-human
To the platelet pellet 100 ll Tyrode’s buffer was
added and analysed by FACS. The rest was incubated
with 2 mM CaCl2 at 37 C for 60 min. Afterwards, the
platelets were centrifuged at 19009g for 10 min and
the supernatant was frozen at -80 C, while the pellet
was dissolved in 100 ll of 0.4 N NaOH (1 h, 45 C)
and again analysed for total protein content.
FACS analysis
Immediately after isolation, 2 ll mouse platelets were
incubated with antibodies against IgG1-FITC (Mil-
teny Biotec, Bergisch Gladbach, Germany, order no.:
130-098-847, 1:25) or CD62P-FITC (BD Biosciences,
Heidelberg, Germany, Cat: 561923, 1:25). Human
platelets were incubated with antibodies against FITC
Mouse IgG1 (BD Biosciences, Cat: 555748, 1:25) or
FITC Mouse Anti-Human CD62P (BD Biosciences,
Cat: 555523, 1:25). Subsequently, 46 ll of FACs
buffer (2 mM EDTA, 0.5 % FCS ad 100 ml PBS, pH
7.1) was added and the samples incubated for 30 min
at 4 C in dark. To study apoptosis, 2 ll of platelets
were incubated with 5 ll Annexin V-FITC (Milteny
Biotec, Order no.: 130-097-928) in 100 ll Annexin V
Binding Buffer (Miltenyi Biotec, 20x Stock Solution)
at RT for 30 min in dark. Immediately before analysis,
2 ll of 7-AAD (Miltenyi Biotec) was added. All
samples were centrifuged at 300g for 10 min and the
pellets were resuspended in 100 ll of FACs flow (BD
FACSFlow). FACs analysis was instantly performed
with a BD FACScan.
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Serotonin analysis by HPLC
Platelet serotonin was measured by high-performance
liquid chromotography (HPLC) as previously de-
scribed in detail by us (Ullrich et al. 2010). Thus, 20 ll
thawed supernatants or extracts were injected on the
HPLC column. As the mobile phase a mixture of
0.05 M trichloric acid (Merck, Darmstadt, Germany),
0.26 mM EDTA, 1.36 mM NaCl, 1.81 mM heptane-
sulfonic acid and 15 % acetonitrile in HPLC water
was used. The components of the samples were
separated on a reversed-phase C18 Nucleosil column
(Bartelt, Graz, Austria) at a flow rate of 1 ml/min. For
the detection of serotonin an electrochemical detector
Antec II was used. The amount of serotonin in the
samples was calculated based on the peak height at the
serotonin-specific retention time (7.8 min).
Western blot analysis
In order to analyse the expression of platelet APP,
Western blot analysis was performed. Five lg acidic
platelet extracts (neutralized with PBS pH 9.5) were
denatured (10 min 70 C) and loaded onto 4–12 % Bis–
Tris polyacrylamide gel (Invitrogen Life Tech, Darm-
stadt, Germany) and separated by electrophoresis for
60 min at 200 V. Consecutively, samples were electro-
transferred to nylon PVDF Immobilon-PSQ membranes
(Millipore, Vienna, Austria) at 30 V for 90 min with
20 % methanol transfer buffer (Invitrogen). Protein
detection was performed with Western Breeze Chemi-
luminescent System (Invitrogen). Thus, membranes
were blocked for 30 min with blocking solution at RT
on the shaker, then incubated with the primary antibody
(Anti-Amyloid beta precursor protein antibody [Y188],
abcam, Cambridge, UK, ab32136) overnight at 4 C.
Following, blots were washed and incubated with anti-
rabbit antibodies for 30 min at RT, again washed and
incubated with CDP-Star chemiluminescent substrate
solution (Invitrogen). Imaging was performed with a
cooled CCD camera SearchLight camera. In order to
quantify the protein amounts in each lane and ensure that
there has been an even transfer from gel to membrane, a
loading control with aMouse IgG was performed.
APP ELISA
Platelet APP was measured using the APP ELISA
(Invitrogen KHB0051, code 310314) kit according to
the instruction manual. Briefly, 50 ll of neutralized
extracts were mixed with 50 ll of standard diluent and
2 ll of sample reducing agent (NuPage, Invitrogen)
and denatured (10 min 70 C) and then put on ice.
Next, 100 ll of each sample/standard was added to the
pre-coated wells, incubated overnight at 4 C, then
washed, 100 ll of biotinylated antibody was added
and again incubated at RT for 1 h. Afterwards, 100 ll
STREP-HRP was added, incubated at RT for 30 min,
washed, 100 ll of chromogen was added and incu-
bated at RT in dark for 30 min. Last, 100 ll of stop
solution was added and measured in the Zenyth
ELISA reader (at 450 nm). The APP values were
calculated according to the standard curve.
sAPPb ELISA
Secreted APPb was analysed using the sAPPb-w
(highly sensitive) Assay Kit—IBL (code 27732,
Immuno-Biological Laboratories, Hamburg, Ger-
many) according to the manufacturer description. In
brief, 12.5 lg of the acidic platelet extracts were
incubated in 50 ll secretase buffer (pH 4.5) for 2.5 h
at 37 C in order to elicit the secretion process.
Subsequently, 50 ll of EIA buffer (1 % BSA, 0.05 %
Tween20 in PBS) was added and a total of 100 ll for
each sample/standard were incubated in the prepared
wells overnight at 4 C, then washed, 100 ll of
labelled antibody was added, incubated for 30 min at
4 C, again washed, 100 ll of chromogen was added
and incubated at RT in dark for 30 min. All incubation
steps were carried out on a shaker. Successively,
100 ll stop solution was added and the luminescent
signal was detected with an ELISA reader Zenyth
3100 and the absorbance was measured at 450 nm.
The samples were calculated according to a standard
curve.
Human EGF ELISA
Platelet EGF levels and EGF release after incubation
were measured using human EGF ELISA kit (Ray-
Biotech, ELH-EGF-001, THP Vienna, Austria). In
short, PBS extracted samples (5 ll) or supernatants
(30 ll) were added in 100 ll diluent into pre-coated
wells, covered and incubated for 2.5 h at RT with
gentle shaking. Next, the solution was washed and
100 ll of biotinylated antibody was added and again
incubated for 1 h at RT. Afterwards, the solution was
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again discarded and washed and 100 ll of Streptavidin
solution was added. After 45 min the solution was
discarded and washed and 100 ll of TMP One-Step
Substrate Reagent was added and incubated for
30 min. Last, 50 ll of Stop Solution was added and
with an ELISA reader Zenyth 3100 the signal was
detected (450 nm). The EGF values were calculated
according to the standard curve.
Statistical analysis
Statistical analysis was performed by one Way
ANOVA with a subsequent Fisher LSD posthoc test
where p\ 0.05 was significant.
Results
Wildtype control mice
Mouse platelets from wildtype mice (C57BL/6N) were
isolated and characterized using FACS analysis, display-
ing a common population and marked CD62P expression
(Fig. 1). Apoptotic and necrotic cell death was very low
in young animals (\0.5 %) and slightly increased in older
mice (\9 %). Serotonin levels were around 60 ng/mg
protein and increased in older animals (Tables 1, 2, 3).
APP like immunoreactivity was detectable in Western
Blot as a single band at approximately 110 kDa (Fig. 2),
but did not markedly change during aging. APP as
measured by ELISA was found to be approximately
2 ng/mg protein which increased in older animals
(Table 3). The release of sAPPb was approximately
3 ng/ml 9 12.5 lg 9 150 min in WT mice.
Hypercholesterolemia mouse model
A cholesterol diet (5 %) for 7, 14 or 20 months did not
significantly affect the platelet APP markers and
serotonin (Table 1). Only a tendency for decreased
sAPPb release was observed in 20 month old hy-
percholesterolemic mice (Table 1).
Triple transgenic AD mouse model
APP 110 kDa as measured by Western Blot sig-
nificantly decreased in 7, and 14 months but not in
20 months old 3xTg mice (Table 2; Fig. 2). A
significant reduction of sAPPb was observed at 7
and 14 months and more pronounced in 20 months old
mice (Table 2). In the 3xTg mice there was a
significant reduction of serotonin levels at 7 months,
which was less noticeable in 14 months old animals
and remained stable at 20 months (Table 2).
APP_SweDI AD mouse model
In this AD mouse model platelets showed markedly
enhanced apoptosis and necrosis as determined by
FACS analysis (Table 3; Fig. 1). Also, significantly
increased CD62P positive cells in 12 months old
transgenic animals were seen (Table 3). APP 110 kDa
did not change at any timepoint compared to controls
(Fig. 2). The release of sAPPb was significantly
reduced at 6 months, but not at 12 months (Table 3).
Serotonin levels were not significantly changed at any
point in time (Table 3).
Human samples
In the human cohort, 43 patients with AD and 30 age-
matched and cognitively healthy persons were includ-
ed. As expected, the MMSE scores were significantly
lower in the AD-group (18 ± 1) compared to healthy
subjects (29 ± 0.3) (Table 4). AD patients were
significantly older (80 ± 1 years) compared to the
healthy volunteers (77 ± 1 years).
Platelets were efficiently isolated (50 ± 2 % IgG1
positive cells in healthy controls and 56 ± 3 % in
patients with AD; Table 4; Fig. 1). FACS analysis
revealed a moderate staining for CD62P (30 ± 3 for
controls and 26 ± 3 % for AD patients) (Table 4;
Fig. 1). Also, moderate necrosis and apoptosis as
visualized by Annexin and 7AAD was observed
(Table 4; Fig. 1).
A reduction in the optical density of the 130 kDa
isoform and a tendency towards a reduction of the
110/106 kDa isoform was found in our present human
cFig. 1 Flow cytometry (FACS) analysis in mouse (a, c, e,
g) and human (b, d, f, h) platelets shows a common population
of cells in forward and sideward scatter (a, b) and markedly
expressed CD62P in mouse (c, green) but less in human (d,
green) platelets, compared to an IgG control (red). Apoptosis
was assessed using Annexin IV staining (e, f), showing
examples of no apoptosis in mice (e) or increased apoptosis in
humans (f, arrow). Necrosis was measured using 7-amino
actinomycin D (7-AAD) in a mouse example (g) or co-
expressed in apoptotic human platelets (h). (Color figure online)
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samples (Fig. 2; Table 4). However, the total platelet
APP levels as measured by ELISA were significantly
increased (Table 4). Using a novel IBL assay kit,
significantly decreased (91.8) secreted APPb in AD
patients was found (Table 4). Although the measured
levels were lower as compared to a previous used
Covance ELISA system, the ratio of this decrease
(91.5) remained similar (Table 4). Finally, a sig-
nificant decrease in platelet EGF levels was found with
a tendency towards increased EGF release (Table 4).
Discussion
Platelets modulate multiple cellular processes includ-
ing angiogenesis and inflammation (Gawaz et al.
2005; Patzelt and Langer 2012) and are involved in a
variety of pathologic conditions where they actively
aggravate vascular changes as e.g. artherosclerotic
events (Gawaz et al. 2005). Since it is known that AD-
pathology is accompanied by both inflammatory and
vascular damaging processes, it seems likely that
Table 1 Hypercholesterolemia mouse model
Months sAPPb APP 110 kDa Serotonin
7
WT 3780 ± 330 (5)- 99 ± 8 (5)- 59 ± 11 (5)-
WT Chol 3600 ± 330 (5) ns 80 ± 8 (5) ns 62 ± 11 (4) ns
14
WT 3809 ± 332 (5) 146 ± 16 (5)- 70 ± 8 (5)-
WT Chol 2097 ± 909 (4) ns 180 ± 29 (5) ns 58 ± 15 (5) ns
20
WT 2077 ± 464 (4) 76 ± 18 (6) 640 ± 127 (5)-
WT Chol 868 ± 396 (4) p = 0.09 105 ± 33 (5) ns 529 ± 163 (5) ns
Wildtype mice (WT) were fed with or without 5 % cholesterol (Chol). At the age of 7, 14 or 20 months platelets from WT or WT-
cholesterol animals were isolated and processed for secreted amyloid precursor protein beta (sAPPb) release, APP and serotonin.
Values are given as mean ± SEM pg/ml 9 25 lg 9 150 min for sAPPb, optical density (OD) for APP and ng/mg protein for
serotonin. Values in parenthesis give the number of animals. Statistical analysis was performed by One Way ANOVA with a
subsequent Fisher-LSD posthoc test
ns not significant
Table 2 Triple transgenic (3xTg) Alzheimer’s disease mouse model
Months sAPPb APP 110 kDa Serotonin
7
WT 3780 ± 330 (5)- 99 ± 8 (5)- 59 ± 11 (5)-
TG 2360 ± 740 (5)* 52 ± 16 (5)* 20 ± 2 (5)**
14
WT 3809 ± 332 (5) 146 ± 16 (5)- 70 ± 8 (5)-
TG 1899 ± 552 (5)* 49 ± 21 (5)** 332 ± 165 (4)*
20
WT 2077 ± 464 (4) 76 ± 18 (6) 640 ± 127 (5)-
TG 580 ± 325 (4)* 55 ± 19 (5) ns 365 ± 123 (5) ns
At the age of 7, 14 or 20 months platelets from wildtype (WT) or 3xTg mice were isolated and processed for secreted amyloid
precursor protein beta (sAPPb) release, APP and serotonin. Values are given as mean ± SEM pg/ml 9 25 lg 9 150 min for sAPPb,
optical density (OD) for APP and ng/mg protein for serotonin. Values in parenthesis give the number of animals. Statistical analysis
was performed by One Way ANOVA with a subsequent Fisher-LSD posthoc test (* p\ 0.05; ** p\ 0.01)
ns not significant
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platelets actively contribute to the progression of AD.
Moreover, besides neurotransmitters, platelets contain
proteins such as APP and produce beta-amyloid and
secretases, making them an interesting target to study
peripheral changes in AD as they may be useful
biomarkers of the disease (Rainesalo et al. 2005; Chen
et al. 1995; Li et al. 1999; Evin et al. 2003). In the
present study we assessed platelet APP, sAPPb and
serotonin in three different mouse models and human
patients with AD; additionally, we evaluated platelet
EGF levels in our human cohort, in order to evaluate
whether these components are altered in AD and
whether platelets are useful as peripheral biomarkers
in AD.
Platelet population, CD62P and apoptosis
Activated platelets undergo a rapid shape change and
redistribute several proteins from their granules to
their surface. In order to trigger the acquisition of
activated platelets with the flow cytometer, surface-
bound P-selectin was identified with a FITC-conju-
gated monoclonal antibody CD62P, a platelet-specific
antigen. A negative control (IgG1) was incorporated in
the protocol and the obtained values substracted from
the CD62P positive events. CD62P is located on the
inner membrane of a-granules and released on the
outside upon activation where it acts as a receptor and
is thus a platelet activation/degranulation marker.
Regarding platelet activation as quantified by CD62P,
contradicting results have been published: an elevated
degree of platelet activation (Sevush et al. 1998), as
well as no difference of membrane-attached P-selectin
without agonist stimulation in AD was reported
(Ja¨remo et al. 2013). Also, increased P-selectin
expression at baseline was found to significantly
associate with faster cognitive decline (Stellos et al.
Table 3 APP_SweDI Alzheimer’s disease mouse model
6 months 12 months
WT TG WT TG
Cell population (%) 66 ± 14 (4) 87 ± 2 (6) ns 77 ± 2 (6) 83 ± 2 (6) ns
CD620P (%) 39 ± 12 (4) 42 ± 11 (6) ns 53 ± 5 (6) 76 ± 3 (6)**
Annexin V (%) 0.5 ± 0.25 (4) 18 ± 5 (6)* 8.4 ± 1.8 (6) 32 ± 8 (6)*
Annexin/7-AAD (%) 0.09 ± 0.02 (4) 2.7 ± 0.7 (6)* 2.4 ± 0.6 (6) 12 ± 4 (6)*
APP WB 110 kDa (OD) 134 ± 47 (7) 129 ± 30 (7) ns 183 ± 18 (6) 140 ± 21 (6) ns
APP (ng/mg protein) 2.1 ± 0.8 (6) 1.4 ± 0.3 (6) ns 9.1 ± 3.1 (5) 12.8 ± 6.7 (6) ns
sAPPb (pg/ml 9 25 lg 9 150 min) 1399 ± 254 (4) 755 ± 88 (6)* 606 ± 144 (6) 403 ± 144 (6) ns
Serotonin (ng/mg protein) 177 ± 78 (5) 223 ± 89 (6) ns 291 ± 99 (6) 397 ± 96 (6) ns
At the age of 6 or 12 months platelets from wildtype (WT) or APP_SweDI (TG) mice were isolated and processed for FACS analysis,
secreted amyloid precursor protein beta (sAPPb) release, APP (Western blot and ELISA) and serotonin. Values are given as
mean ± SEM; values in parenthesis give the number of animals. Statistical analysis was performed by One Way ANOVA with a
subsequent Fisher-LSD posthoc test (* p\ 0.05; ** p\ 0.01)
ns not significant, OD optical density, WB Western blot
Fig. 2 Western blot analysis of amyloid precursor protein
(APP) immunoreactivity in mouse (a) or human (b) platelets. In
mice, one single APP band was seen at approx. 110 kDa in
wildtype (WT), triple transgenic (3xTg), cholesterol (Chol) or
APP_SweDI (SweDI) mice. Loading control was performed
using anti-mouse IgG showing a band at 55 kDa (a). In humans,
2 bands were visible one larger at approximately 130 kDa and a
smaller at approximately 110/106 kDa (b). The larger 130 kDa
band declined in Alzheimer’s disease patients (AD) compared to
controls (b). Actin at 42 kDa served as a loading control
Biogerontology (2015) 16:543–558 551
123
2010). In the present study we did not find significantly
increased membrane-attached P-selectin expression in
human patients with AD and young APP_SweDI mice.
However, we found a significant increase in CD62P
binding in 12 month old APP_SweDI mice. This was
accompanied by enhanced cell death as visualized
with 7-aminoactinomycin D and significantly higher
apoptoptis as seen with Annexin V. This suggests that
platelets, besides increased activation, are also more
sensitive to cell death in the AD mouse model. In
contrast, human patients did not show altered platelet
populations compared to healthy controls suggesting
that mouse platelets are more vulnerable or that the
AD mice do not fully display the human AD
pathology.
Serotonin
Once released, platelet-derived serotonin modulates
platelet aggregation at sites of vascular injury. As it
has been demonstrated that activated platelets aggre-
gate at sites of vascular Ab promoting CAA by
inducing platelet thrombus formation (Roher et al.
2009; Gowert et al. 2014), it is tempting to assume
serotonin alterations in AD.
In the present study we observed significantly
reduced platelet serotonin concentration in 3xTg mice
at early stage. This can be due to both, enhanced
platelet activity or decreased serotonin uptake in these
transgenic mice. However, we did not see any
alterations of serotonin concentrations in dietary
hypercholesterolemia mouse models, APP_SweDI
animals and human patients with AD. Thus, while
some studies report reduced platelet serotonin content
in hypercholesterolemia subjects and animal models
(Smith and Betteridge 1997; Ogawa et al. 2000), we
cannot report similar findings in our hypercholes-
terolemia mouse population.
Previous studies including ours failed to demon-
strate altered serotonin processing in AD (Tukiainen
Table 4 Human platelets
Controls AD
Age (years) 77 ± 1 (30) 80 ± 1 (43)*
Sex (m/f) 10/20 18/25 ns
MMSE 29 ± 0.3 (30) 18 ± 1 (43)***
Cell population (%) 50 ± 2 (30) 56 ± 3 (43) ns
CD62P (%) 30 ± 3 (30) 26 ± 3 (43) ns
Annexin (%) 29 ± 3 (30) 33 ± 4 (43) ns
Annexin/7ADD (%) 15 ± 2 (30) 18 ± 2 (43) ns
APP 130 kDa (OD)a 75 ± 10 (15) 38 ± 7 (25)*
APP (110/106 kDa) (OD)a 71 ± 9 (15) 42 ± 8 (25) p = 0.08
APP (ng/mg protein) 2.6 ± 0.3 (30) 3.3 ± 0.2 (43)*
sAPPb (pg/ml 9 25 lg 9 150 min)c 519 ± 50 (33) 1548 ± 211 (68)***
sAPPb (pg/ml 9 25 lg 9 150 min) 402 ± 102 (26) 924 ± 174 (41)*
Serotonin (ng/mg protein)b 565 ± 79 (11) 529 ± 88 (22) ns
Serotonin (ng/ml 9 mg 9 h) 22 ± 7 (30) 16 ± 5 (39) ns
EGF (pg/mg protein) 365 ± 56 (25) 170 ± 66 (36)*
EGF (pg/ml 9 mg 9 h) 66 ± 7 (25) 87 ± 9 (36) p = 0.09
Platelets were isolated from healthy controls or Alzheimer’s disease patients (AD) and processed for FACS analysis, secreted
amyloid precursor protein beta (sAPPb) release, APP (Western Blot and ELISA), serotonin or EGF. Values are given as
mean ± SEM; values in parenthesis give the number of patients/controls. Statistical analysis was performed by Student’s t test
(* p\ 0.05; *** p\ 0.001)
ns not significant, OD optical density, MMSE, mini mental state examination
a Taken from Ehrlich et al. (2013) Platelets 24:26–36
b Taken from Hochstrasser et al. (2012b) Curr. Alzheimer Res. 9:982–989
c Taken from Marksteiner and Humpel (2013) Curr. Neurovasc. Res. 10:297–303 using a Covance ELISA
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et al. 1981; Andersson et al. 1991; Hochstrasser et al.
2012b), while a number of studies reported impaired
uptake of platelet serotonin (Koren et al. 1993;
Inestrosa et al. 1993) and significantly lower platelet
serotonin concentration (Proksˇelj et al. 2014; Mimica
et al. 2008; Muck-Seler et al. 2009). These findings
stand in contrast to other studies, postulating increased
serotonin concentration (Kumar et al. 1995, Milo-
vanovic et al. 2014). The discrepancy of these results
may arise from different AD stages, as well as from
diurnal and seasonal variations of serotonin (Muck-
Seler et al. 2009; Meyerson et al. 1989). We conclude
that platelet serotonin levels fluctuate and have a high
variability, and are therefore not suited as a reliable
biomarker for AD.
Amyloid-precursor protein in platelets
Platelets are an important peripheral source of APP,
and three major isoforms (770, 751 and 695) are
inserted in the membrane of resting platelets (Gardella
et al. 1990; Bush et al. 1990; Di Luca et al. 2000).
While APP695 lacks the KPI and OX-2 domains and is
mainly expressed in neuronal cells, platelets prefer-
ably express the two KPI containing APP isoforms 770
and 751 (Tanzi et al. 1988; Golde et al. 1990; Mo¨nning
et al. 1992; Li et al. 1994). Additionally, platelets are
also equipped with a-, b-, and c-secretases, thus being
able to generate different Ab fragments (Colciaghi
et al. 2004). Up to date, the physiological role of APP
and its metabolites in platelets is not fully understood.
In several studies including ours, platelet APP ratio
between the larger and lower isoforms of AD patients
is significantly lower compared to healthy control
subjects and correlate with disease severity (Di Luca
et al. 1996, 1998, 2000; Borroni et al. 2004; Padovani
et al. 2001; Baskin et al. 2000; Rosenberg et al. 1997;
Zainaghi et al. 2012; Ehrlich et al. 2013). However,
APP has not yet been established as a diagnostic
biomarker for early AD (Zainaghi et al. 2012; Srisawat
et al. 2013) because of its low diagnostic accuracy and
methodological problems. In the present study, we
confirm that platelet APP ratio is decreased, but we
included in addition to Western Blot a quantitative
analysis of the present cohort where we found the
opposite trend. Moreover, we show for the first time
that APP 110 kDa isoform is reduced in the triple
transgenic AD mouse model. This suggests that the
3xTg AD mouse model shares some similarities with
the human AD pathology and indeed this model
displays plaques as well as Tau pathology. Accord-
ingly, the APP 110 kDa isoform was unchanged in the
hypercholesterolemia and APP_SweDI mouse mod-
els. In contrast to the findings that APP isoforms are
decreased, our present study shows that the quantita-
tive ELISA analysis of total APP reveals rather an
increase of APP in human samples. While this seems
to be a mismatch, it is likely that the ELISA system
recognizes several forms of APP including secreted
APP forms. Thus, the Western Blot is a more accurate
method to differentiate between the APP isoforms.
The development of an ELISA system highly specific
for the 130 kDa isoform may be of potential interest to
increase reproducibility and sensitivity.
Secreted APPb
Secreted APPb is released as an extracellular cleavage
product after the first step within the amyloidogenic
processing of APP. While the function of sAPPb is not
entirely clear, it has been proposed that secreted APP has
neuroprotective and synapse promoting activities in the
brain (Bandyopadhyay et al. 2007). Both, sAPPb and
sAPPa were moreover associated with decreased cell
adhesion and increased axon elongation in vitro (Chas-
seigneaux et al. 2011). Our group has recently investi-
gated both platelet sAPPb and sAPPa levels, finding that
sAPPb but not sAPPa is markedly increased in MCI and
AD patients (Marksteiner and Humpel 2013). In the
present study we confirm a significantly increased
sAPPb release in AD patients. However, the formerly
used Covance ELISA resulted in slightly higher levels
of sAPPb compared to the IBL ELISA used in this study.
The observed increase of sAPPb release is an indicator
for enhanced APP cleavage in platelets of patients with
AD. In contrast to the increase of sAPPb release in AD
patients, we found significantly decreased sAPPb
release in two transgenic mouse models (3xTg and
APP_SweDI) and additionally a trend towards reduced
sAPPb release in old (20 months) hypercholesterolemia
mice. This controversy may be again due to the different
pathological framework of mouse models and human
patients. Altogether, while finding an opposed trend in
mouse and humans, we were able to replicate our
previous findings in human patients with a different
ELISA assay. Thus, platelet sAPPb release may repre-
sent therefore an interesting target worth further
investigation.
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Epidermal growth factor in platelets
Growth factors play an important role in proliferation,
differentiation and growth of numerous cell types.
Platelets contain several growth factors, amongst
others EGF, vascular endothelial growth factor or
platelet-derived growth factor. Along with other
proteins, EGF was found to be increased in plasma
of patients with AD (Marksteiner et al. 2011;
Bjo¨rkqvist et al. 2012). As previously reported by
our group, platelet EGF was significantly reduced in
patients with AD (Hochstrasser et al. 2012b). In the
present study we confirm that platelet EGF is reduced
in AD patients. This reduction as seen in our studies
stands in concordance with a described increase of
plasma EGF levels, possibly caused by a continuous
release of EGF by platelets under AD-conditions.
Comparison mouse and human platelets
This study shows that platelets undergo distinct
changes in mouse models of AD and patients with
AD compared to either wild type animals or cogni-
tively healthy subjects. The results for AD mouse
models are consistent for a decrease in APPb secre-
tion, which was found in both transgenic animal
models. However, this alteration was inversely pro-
nounced in human samples, where we observed a
significant increase in secreted APPb in patients with
AD. The reduction of the optical density of APP
(130 kDa) in humans is likewise observed in the
110 kDa isoform of 3xTg animals. An inconsistency
was observed for serotonin levels and serotonin
release with significant changes only in the triple
transgenic model. A decrease in platelet EGF levels in
human patients with AD confirms our previous
findings. The overall results indicate that changes in
AD are not limited to the central nervous system, but
co-occur in peripheral blood cells such as platelets.
More specifically, platelet EGF levels are altered in
patients with AD and platelet APP expression and
secretion is altered in AD patients with supporting
evidence from AD mouse models. Both proteins, APP
and EGF are worth further investigation as they may
be useful peripheral biomarkers for AD. Hypercholes-
terolemia did not significantly trigger platelet changes
in AD mouse models, supporting the hypothesis that
the observed changes are AD-specific, while a
cholesterol diet alone does not alter platelet serotonin
levels, APP expression or the secretion of APPb.
However, there are noticeable differences among
the three mouse models and human patients with AD.
The differences among the models and AD patients
may reflect pathophysiological and neuropathological
differences. Although we assessed platelets of highly
valid transgenic animal models of AD and hy-
percholesterolemia mice with comparable cognitive
deficits, none of the currently available models reca-
pitulates all pathological conditions of the human AD
brain and they appear limited in mirroring sensitive
peripheral changes as seen in the present study.
Moreover, while mice represent an excellent model
for studying platelet biology in vivo because murine
platelets share properties with human platelets, they
differ per se in some ultrastructural characteristics. We
also found that platelets of a transgenic AD mouse
population are generally more susceptible for apopto-
sis and necrosis compared to human platelets. While
the significant tendency of reduced APP (130 kDa) as
seen by Western blot in human patients with AD was
supported by findings in our 3xTg group (110 kDa), the
secretion of APPb in transgenic animals is reversely
pronounced as compared to humans. The discrepancy
found in the secretion of APPb by platelets demon-
strates that murine peripheral APP is diversely pro-
cessed in response to pathological conditions that are
only of limited dimension compared to those seen in
humans. Since APP secretion is closely linked to
platelet activation, the observed difference may pos-
sibly be due to altered platelet reactivity in mouse
models as seen by enhanced CD62P expression and
cell death. Because platelet APP expression and
processing seem overall affected in early and late
AD, this protein represents a highly interesting target
worth further investigation within the search for
peripheral biomarkers in human subjects. Likewise,
the reduction of platelet EGF levels may be a
promising marker for AD-related changes and is in
need of further evaluation.
Limitations of the study including methodological
problems
(1) The cross-sectional design of this experiment
precludes the long-term and time-dependent variation
of the different platelet components. The biological
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effects of all measured biomarkers may vary with
different stages of diseases and at different points of
time. (2) Due to low sample volumes (1 ml EDTA
blood from mice), EGF and FACS analysis could not
be performed in the mouse models compared to
humans (10 ml EDTA blood). (3) The number of
human participants included in this study is relatively
low. (4) In this study, only AD patients were included.
Further studies are needed to understand, whether the
observed alterations are AD-specific in terms of their
ability to distinguish AD from clinically similar
dementia forms. (5) Platelets are sensitive cells and
require careful handling during preparation. After
decades of study, there is still a general need to
establish concurrent methods for the different pro-
cessing steps of platelets because the wide variation of
reported protocols for platelet preparation leads to
different biological responses and incomparable data.
Several variables (such as e.g. anticoagulants in
collection tubes, time of processing, etc.) in the
platelet preparation process need to be standardized
to minimize artificial stimulation during blood collec-
tion and sample handling.
Conclusion
Biomarkers may have an immense scientific and
clinical value through the whole progression of a
disease. Our data support the hypothesis that platelets
are dysfunctional in AD and AD-like conditions,
however, to date no AD-specific platelet biomarker
has been clinically established. The inconsistencies of
intra- and inter-person variability may account for this
problem. We further show that transgenic mice do not
fully display the human AD pathology also in respect
of platelet alterations. Altogether, we believe that
platelet biomarkers may become very useful in
diagnosing early and late AD.
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